Drug Trial Radar · NCT05189444
The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori
Last checked: Nov 20, 2026Latest source record: Mar 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
672
Planned (sponsor's estimate)
Start
Mar 25, 2022
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 12, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. The aim of this prospective study is to investigate the efficacy of Triple Therapy with Vonoprazan, Amoxicillin, and Bismuth for eradication of Hp, compared with standard quadruple therapy.
Conditions
- Helicobacter Pylori Infection
Interventions
VonoprazanDrug
20mg bid
AmoxicillinDrug
0.75g tid
EsomeprazoleDrug
20mg bid
AmoxicillinDrug
1.0g bid
ClarithromycinDrug
0.5g bid
Bismuth potassium citrateDrug
0.22g bid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Helicobacter pylori eradicationTime frame: 6 weeks after treatment initiation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital, Tongji Medical College, HUST
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.